BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10454204
• 负责人: SUBHRA MOHAPATRA
• 金额: --
• 依托单位: JAMES A. HALEY VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-04-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10454204
• 关键词: 3-Dimensional; Acute; American; Anti-Inflammatory Agents; Antineoplastic Agents; Area; Atrial Natriuretic Factor; Award; CCL20 gene; Cancer Etiology; Cardiac; Cell Therapy; Clinic; Clinical; Collaborations; Colon Carcinoma; Colorectal Cancer; Combined Modality Therapy; Common Cold Virus; Development; Diagnostic; Disease; Drug Delivery Systems; Educational process of instructing; Effectiveness; Extramural Activities; FDA approved; Face; Florida; Funding; Future; Grant; Health; Hospitals; Human; Immunocompetent; In Vitro; Inflammation; Injury; International; Iraq; Journals; Laboratory Finding; Lead; Legal patent; Literature; Malignant Neoplasms; Malignant neoplasm of brain; Malignant neoplasm of lung; Memory Loss; Mentors; Mesenchymal Stem Cells; Military Personnel; Modeling; Neoplasm Metastasis; Nerve Regeneration; Oncolytic; Organoids; Pharmaceutical Preparations; Phase; Play; Polymers; Proteins; Publications; Rattus; Relapse; Reporting; Research; Research Activity; Research Personnel; Research Support; Respiratory syncytial virus; Role; Safety; Scientist; Screening procedure; Seeds; Seminal; Services; Small Business Innovation Research Grant; Small Interfering RNA; Societies; TBI treatment; Technology; Testing; Therapeutic; Time; Training; Translating; Translational Research; Traumatic Brain Injury; Treatment Efficacy; Tumor Biology; United States Department of Veterans Affairs; United States National Institutes of Health; Universities; Veterans; Work; anti-cancer; base; cancer biomarkers; cancer diagnosis; cancer stem cell; cancer therapy; career; chemokine; colorectal cancer prevention; colorectal cancer treatment; combinatorial; controlled release; drug discovery; effective therapy; experience; graduate student; indexing; innovation; mid-career faculty; military veteran; mouse model; mutant; nano; nanofiber; nanomicelles; nanoscale; neoplasm registry; neoplastic cell; novel; novel anticancer drug; novel therapeutics; programs; receptor; scaffold; stem cell therapy; stem cells; systemic inflammatory response; targeted agent; therapeutic evaluation; three dimensional cell culture; time use; tumor; tumor growth; tumor microenvironment

This application is for a Research Career Scientist Award for Dr. Subhra Mohapatra (nominee) who is a research microbiologist at the James A. Haley VA Hospital, Tampa, FL, and an Associate Professor at the VA-affiliated academic center, the University of South Florida. Since 2007, the nominee has been contributing significantly to VA research and services via training, mentoring and collaboration with VA investigators. She is recognized nationally and internationally for her contributions to the field of tumor biology, particularly pertaining to mechanism of tumor- stroma interactions, 3D culture-based anti-cancer drug discovery, and nanoscale anti-cancer drug delivery approaches. She has contributed significantly to scientific literature including over 61 publications, which have generated ~2419 citations and a cumulative H-Index of 28 and i10-Index of 45. She also holds 12 US patents. Dr. Mohapatra has received substantial extramural research support (~$13 million) including awards from the NIH, ONR, Department of Veterans Affairs and Florida Department of Health. She also served as guest editor of the Journal of Drug Delivery and Translational Research (a journal of the Controlled Release Society) special issue entitled “NanoBio Interface: From Lab to Clinic.” She was selected for “Faces of Technology” by the Florida High Tech Corridor and was awarded the 2014 Excellence in Innovation award by the USF Office of Research and Innovation. Dr. Mohapatra has been funded with the two Merit Review Awards. She has initiated a third project for a future Merit proposal. Current research activities supported by VA Merit Review (VMR) are summarized below. VMR Project #1 (2016-2019). Investigate the potential of a novel combinatorial therapeutic approach in a rat model of moderate TBI that includes (i) a treatment to reduce inflammation (local and systemic) using a nano-formulated siRNA against a recently discovered target, CCL20, and (ii) a second treatment to promote neuroregeneration by mesenchymal stem cell (MSC) therapy. VMR Project #2 (2017-2021). Investigate the potential of a novel targeted oncolytic viro-cell therapy using MSCs infected by a common cold virus, respiratory syncytial virus (RSV), for lung cancers. The project involves infecting hMSCs with wild type or mutant RSV and testing them in vitro using 3D tumoroid platform and then testing their anti-cancer potential using immunocompetent syngeneic orthotopic model of lung cancer. In addition, she serves as a co-I in a third VMR project that focuses on RSV. Project #3 (VMR project in development). Discover and investigate the potential of novel anticancer agents targeting cancer stem cells (CSCs) for the treatment of colorectal cancer (CRC). The project involves use of 3D tumoroid platform to screen for anticancer agents that will inhibit expansion of CRC-CSCs and then testing therapeutic efficacy of these agents in mouse model of CRCs. These highly innovative programs taken together are expected to lead to high impact therapies for diverse diseases for Veterans and other Americans in need. In summary, Dr. Mohapatra will be highly effective as a Research Career Scientist creating national impacts in training, mentoring, research and services at the VA.

此申请适用于 Subhra Mohapatra 博士的研究职业科学家奖 （被提名人）是佛罗里达州坦帕市 James A. Haley VA 医院的一名研究微生物学家， 自 VA 附属学术中心南佛罗里达大学副教授以来。 2007 年，被提名者通过培训为 VA 研究和服务做出了重大贡献， 她与 VA 研究人员的指导和合作在国内和国际上得到认可。 表彰她在肿瘤生物学领域，特别是在肿瘤机制方面的贡献 基质相互作用、基于3D培养的抗癌药物发现和纳米级抗癌药物 她对科学文献做出了重大贡献，其中包括超过 61 篇文献。 出版物，已产生约 2419 次引用，累计 H 指数为 28 和 i10 指数 45. 她还拥有 12 项美国专利。Mohapatra 博士接受了大量的校外研究。 支持（约 1300 万美元），包括来自 NIH、ONR、退伍军人事务部和 她还担任佛罗里达州卫生部《药物输送杂志》的客座编辑。 转化研究（控释协会期刊）特刊，题为“NanoBio 界面：从实验室到诊所。”她被佛罗里达高科技公司选为“技术面孔” Corridor 并被 USF 研究办公室授予 2014 年卓越创新奖 Mohapatra 博士获得了她发起的两项优秀评审奖的资助。 未来优异提案的第三个项目 目前的研究活动由 VA 优异评审支持。 (VMR)总结如下。 VMR 项目#1（2016-2019）研究新型组合疗法的潜力。 中度 TBI 大鼠模型的方法，包括 (i) 减少炎症的治疗（局部炎症） 和全身）使用纳米配方的 siRNA 针对最近发现的靶标 CCL20，以及 (ii) 第二种治疗方法是通过间充质干细胞（MSC）疗法促进神经再生。 VMR 项目#2（2017-2021）研究新型靶向溶瘤病毒细胞的潜力。 使用感染普通感冒病毒、呼吸道合胞病毒 (RSV) 的 MSC 进行肺部治疗 该项目涉及用野生型或突变型 RSV 感染 hMSC 并进行体外测试。 使用 3D 肿瘤样平台，然后使用免疫活性测试其抗癌潜力 此外，她还是第三个 VMR 项目的共同成员。 重点关注 RSV。 项目 #3（正在开发的 VMR 项目）。发现并研究小说的潜力。 针对癌症干细胞（CSC）的抗癌药物用于治疗结直肠癌（CRC）。 该项目涉及使用 3D 类肿瘤平台来筛选能够抑制 CRC-CSC 的扩增，然后在小鼠模型中测试这些药物的治疗效果 CRC。 这些高度创新的计划结合在一起预计将产生巨大影响 总而言之，为退伍军人和其他有需要的美国人提供多种疾病的治疗方法。 莫哈帕特拉将成为一名高效的研究职业科学家，在以下领域创造国家影响力： VA 的培训、指导、研究和服务。